Page last updated: 2024-12-09

[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

**[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone** is a complex organic molecule that has shown potential in various research areas, particularly in the field of **drug discovery**.

**Structure and Properties:**

* **Triazole ring:** The molecule contains a 1,2,4-triazole ring, a heterocyclic ring system known for its versatility and biological activity.
* **Thiophene ring:** The presence of a thiophene ring, a sulfur-containing aromatic system, often contributes to enhanced pharmacological properties.
* **Benzyl groups:** The molecule incorporates two benzyl groups (phenylmethyl), which can influence its lipophilicity and interaction with biological targets.
* **Ketone group:** The ketone group at the thiophene-2-yl position can play a role in its binding affinity to receptors or enzymes.

**Research Importance:**

**1. Anti-cancer Activity:** Studies have shown that [3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone exhibits **anti-proliferative effects** against various cancer cell lines, including breast, lung, and colon cancer cells. This suggests its potential as a novel anti-cancer agent.

**2. Anti-inflammatory Activity:** The molecule has been found to possess **anti-inflammatory properties** in vitro and in vivo models. This activity stems from its ability to inhibit the production of pro-inflammatory mediators like TNF-α and IL-6.

**3. Antioxidant Activity:** Research indicates that this compound exhibits **antioxidant activity** by scavenging free radicals and protecting cells from oxidative stress. This property makes it a potential candidate for treating diseases associated with oxidative damage.

**4. Other Applications:**
* **Pharmaceutical development:** The molecule's diverse biological activity and structural features make it a valuable lead compound for developing new pharmaceuticals targeting various diseases.
* **Material science:** The unique combination of aromatic rings and functional groups could potentially lead to applications in materials science, such as organic semiconductors or photoactive compounds.

**Conclusion:**

[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone is a promising molecule with significant potential in research, particularly in drug discovery. Its anti-cancer, anti-inflammatory, and antioxidant properties warrant further investigation to explore its therapeutic benefits.

Cross-References

ID SourceID
PubMed CID2243417
CHEMBL ID1582259
CHEBI ID122065

Synonyms (12)

Synonym
MLS000583329
smr000201679
n,n'-dibenzyl-1-(2-thienylcarbonyl)-1h-1,2,4-triazole-3,5-diamine
[3,5-bis(benzylamino)-1h-1,2,4-triazol-1-yl](thiophen-2-yl)methanone
STK178825
CHEBI:122065
AKOS001944666
HMS2528B15
[3,5-bis(benzylamino)-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone
CHEMBL1582259
Q27210696
[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
thiophenesCompounds containing at least one thiophene ring.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency1.77830.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency6.30960.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency25.92900.004110.890331.5287AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1468
chromobox protein homolog 1Homo sapiens (human)Potency25.11890.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.62340.00798.23321,122.0200AID2546
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency3.98110.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]